Persons using assistive technology might not be able to fully access information in this file. For assistance, please send e-mail to: email@example.com. Type 508 Accommodation in the subject line of e-mail.
Lyme Disease -- Connecticut
From 1984 through 1986, CDC received an average of 1,500 reports of Lyme disease annually, making it the most common tick-borne disease reported to CDC. The disease takes its name from Lyme, Connecticut, where the full spectrum of illness was first described in 1975. To further study the incidence of disease among its residents, Connecticut conducted a laboratory-based program of surveillance for Lyme disease from July 1, 1984, to March 1, 1986.
Indirect immunofluorescence antibody (IFA) and enzyme-linked immunosorbent assays (ELISA) were used to detect antibodies to Borrelia burgdorferi, the spirochete that causes the disease. Serologic testing was offered to Connecticut physicians without cost for all residents with suspected Lyme disease if the serum was accompanied by a case report form. Residents who, in 1984 or 1985, had onset of erythema migrans* and/or neurologic, cardiac, or arthritic manifestations** characteristic of Lyme disease and a positive serologic test (IFA greater than or equal to1:128 or ELISA greater than or equal to1:160 with a polyvalent conjugate) were included in the study.
Thirty-seven percent of the 3,098 patients reported met the criteria for inclusion in the study (460 in 1984 and 689 in 1985). In 1985, the first complete year of reporting, 66% of the patients studied had onset of symptoms from June through August. Twenty-four percent more patients had onset of symptoms from July through December 1985, than from July through December 1984 (492 compared with 397).
Thirty-seven percent of the 3,098 patients reported met the criteria for inclusion in the study (460 in 1984 and 689 in 1985). In 1985, the first complete year of reporting, 66% of the patients studied had onset of symptoms from June through August. Twenty-four percent more patients had onset of symptoms from July through December 1985, than from July through December 1984 (492 compared with 397). Serologic testing was equally available during these time periods.
The incidence of Lyme disease for all Connecticut residents in 1985 was 22/100,000. Town-specific incidences ranged from zero to 1,156/100,000. Towns with the highest incidences were in southern Connecticut, east of the Connecticut River.
Fifty-one percent of patients with Lyme disease were male, and all but one of the 372 patients with known race reported in 1984 were white. Racial information was not gathered in 1985. Age-specific incidence was tabulated by 5-year age groups for patients reported in 1985. The incidence ranged from 11/100,000 for persons aged 20 to 24 years, to 39/100,000 for those aged 5 to 9 years (Figure 1).
Overall, 83% of the patients studied had erythema migrans; 24% had but one of the 372 patients with known race reported in 1984 were white. Racial information was not gathered in 1985. Age-specific incidence was tabulated by 5-year age groups for patients reported in 1985. The incidence ranged from 11/100,000 for persons aged 20 to 24 years, to 39/100,000 for those aged 5 to 9 years (Figure 1).
Overall, 83% of the patients studied had erythema migrans; 24% had arthritis; 8% had neurologic manifestations; and 2% had cardiac involvement. For those with arthritis, affected joints were the knee (89%), hip (9%), shoulder (9%), ankle (7%), and elbow (2%). In 1985, persons under 20 years of age were 1.6 times more likely to have arthritis than persons over 20 (7/100,000 compared with 4/100,000), while both groups were equally likely to develop erythema migrans (13/100,000). Seventy-nine percent of patients with arthritis did not report antecedent erythema migrans. Sixty-one percent of patients with erythema migrans reported a tick bite within 30 days of illness.
Sera received before July 1, 1985, (1,447 samples) were tested by IFA; sera received later (1,579 samples) were tested by ELISA; and 72 patients were reported without a request for serologic testing. For those with erythema migrans, the overall sensitivity of serology was 30% by IFA and 24% by ELISA. When the serum sample had been obtained 21 days or more after onset of symptoms, the sensitivity of the IFA increased to 45% and that of the ELISA, to 32%. Reported by: LA Magnarelli, PhD, Connecticut Agricultural Experiment Station, New Haven; RW Ryan, PhD, RC Tilton, PhD, Univ of Connecticut School of Medicine; JA Hardin, MD, Yale Univ School of Medicine; DC Niejadlik, MD, Middlesex Memorial Hospital, Middletown; AH Sweeney, MPH, ML Cartter, MD, PJ Checko, MPH, PA Mshar, HC Chaski, MPH, JL Hadler, MD, MPH, State Epidemiologist, Connecticut State Dept of Health Svcs. AC Steere, MD, Tufts Univ School of Medicine, Boston, Massachusetts. Meningitis and Special Pathogens Br, Center for Infectious Diseases; Div of Field Svcs, Epidemiology Program Office, CDC.
Editorial Note: This study demonstrates the impact of Lyme disease in an endemic area. A comparison of the results with those of a 1977 study (1) reveals an increase of 163% in the incidence of Lyme disease in the eight towns reporting cases in 1977 and shows that, by the mid-1980s, the disease had spread inland from the coastal areas.
Serologic testing for Lyme disease has increased considerably in Connecticut. To trace these changes in testing, the state health department recently compared the annual number of immunoglobulin or IgG-specific serologic tests for Lyme disease ordered by Connecticut physicians from January 1984 through August 1987. The number and results of these tests varied by year as follows: 2,492 in 1984 (30% positivity), 3,770 in 1985 (20% positivity), 5,175 in 1986 (24% positivity), and 6,420 through August of 1987 (14% positivity). This increase may reflect an actual increase in the incidence of Lyme disease or in the recognition of the disease by physicians. It may also reflect the increased availability of the laboratory test or its overuse, especially during the early stage of the disease, when the test is likely to be negative (2-4).
The diagnosis of early Lyme disease remains primarily clinical, and physicians should be aware of the limitations of current tests. Sensitivities of the IFA and the ELISA are relatively low during stage one (2-4), and the antibody response can be curtailed or aborted by early treatment with antibiotics (3). In contrast, some research laboratories have reported sensitivities greater than or equal to95% for tests of patients with stage two or three Lyme disease (2,4,5). Test specificities approaching 100% have also been reported (2,6); however, considerable variability may occur among laboratories because the tests are not standardized and are difficult to perform. The sensitivities and lack of standardization of the tests preclude their use alone for routine disease reporting and reinforce the need to develop a reliable and practical case definition for surveillance that is not dependent on serologic test results.
Lyme disease is a problem of increasing national and international concern that merits continual and improved surveillance. Clinical studies to further define complications of the disease and to evaluate treatment regimens are needed. Public health education can help alert people to the symptoms of Lyme disease and to the importance of avoiding tick bites. The development of other effective primary preventive measures, particularly vector control, is essential.
Disclaimer All MMWR HTML documents published before January 1993 are electronic conversions from ASCII text into HTML. This conversion may have resulted in character translation or format errors in the HTML version. Users should not rely on this HTML document, but are referred to the original MMWR paper copy for the official text, figures, and tables. An original paper copy of this issue can be obtained from the Superintendent of Documents, U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800. Contact GPO for current prices.**Questions or messages regarding errors in formatting should be addressed to firstname.lastname@example.org.
Page converted: 08/05/98
This page last reviewed 5/2/01